The estimated Net Worth of Dennis M Mcgrath is at least $1.83 millió dollars as of 21 December 2022. Mr Mcgrath owns over 9,872 units of PAVmed Inc stock worth over $118,096 and over the last 8 years he sold PAVM stock worth over $1,190,215. In addition, he makes $517,700 as Pres és CFO & Corp. Sec. at PAVmed Inc.
Mr has made over 6 trades of the PAVmed Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 9,872 units of PAVM stock worth $39,192 on 21 December 2022.
The largest trade he's ever made was selling 67,787 units of PAVmed Inc stock on 26 May 2021 worth over $1,151,023. On average, Mr trades about 2,366 units every 49 days since 2016. As of 21 December 2022 he still owns at least 74,744 units of PAVmed Inc stock.
You can see the complete history of Mr Mcgrath stock trades at the bottom of the page.
Dennis M. McGrath CPA is the Pres, CFO & Corp. Sec. at PAVmed Inc.
As the Pres és CFO & Corp. Sec. of PAVmed Inc, the total compensation of Mr CPA at PAVmed Inc is $517,700. There are 2 executives at PAVmed Inc getting paid more, with Dr. Lishan Aklog M.D. having the highest compensation of $686,300.
Mr CPA is 64, he's been the Pres és CFO & Corp. Sec. of PAVmed Inc since . There are 2 older and 8 younger executives at PAVmed Inc. The oldest executive at PAVmed Inc is James Cox, 77, who is the Independent Director.
Dennis's mailing address filed with the SEC is 322 W 57TH ST, #33B18, , NEW YORK, NY, 10019.
Over the last 9 years, insiders at PAVmed Inc have traded over $1,291,924 worth of PAVmed Inc stock and bought 370,262 units worth $523,987 . The most active insiders traders include Ira Scott Greenspan, Matthew Sirovich és Michael J Glennon. On average, PAVmed Inc executives and independent directors trade stock every 73 days with the average trade being worth of $62,625. The most recent stock trade was executed by Michael J Glennon on 5 December 2022, trading 250,000 units of PAVM stock currently worth $160,000.
pavmed is a groundbreaking medical device company bringing innovative medical technologies from concept to commercialization with unprecedented speed and efficiency. led by three accomplished medical device entrepreneurs and organized to conceive, develop and commercialize a diversified pipeline of innovative products we believe address unmet clinical needs, our goal is to enhance and accelerate value creation by employing a business model focused on capital and time efficiency.
PAVmed Inc executives and other stock owners filed with the SEC include: